Skip to main content

Market Overview

3 COVID Stocks Not To Neglect

3 COVID Stocks Not To Neglect

There are now over 60 million COVID-19 cases worldwide, and they're continuing to rise. Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) gave the world hope as their candidates showed 90% efficacy. But, besides these pharma stars, there are many other COVID-19 stocks that shouldn't be neglected.

Uncovering a new opportunity

The impending release of the above vaccines has created an abundant opportunity for companies that supply ultra-low temperature freezers as well as those which will ship them across the globe. Thermo Fisher Scientific (NYSE: TMO) and United Parcel Service (NYSE: UPS) are up to the task.


Demand for freezers could be through the roof as Pfizer's vaccine needs to be stored at negative 70 degrees Celsius, which is South Pole-like temperature, unlike Moderna's vaccine that requires a regular freezer at 20 degrees Celsius. Thermo Fisher's ULT freezers can accommodate both, as they can reach temperatures as low as negative 80 degrees Celsius. The created demand for these freezers will likely result into an improved top and bottom line for the healthcare company which is already a solid investment on its own merits. Besides consistently delivering a profit over the ten previous quarters, sales from lab products and services rose 11.1% YoY to $8.6 billion during the first nine months of the year, whereas total sales this year increased 15.8% from the same period last year, amounting $21.7 billion.


UPS will also keep being busy with the vaccine after already being engaged with a rise in online shopping and deliveries during the pandemic. On November 24th, the company stated it has the capability to make up to 1,200 pounds of dry ice per hour. Moreover, by partnering with Stirling Ultracold, it will help supply ULT freezers so it can provide more than just a temporary storage solution. However, given the uncertainty surrounding the pandemic, the company did not provide any guidance or estimates pertaining to revenue for the fourth quarter.  Year to date, UPS stock has climbed 44%.

Don't dismiss J&J just yet

Despite dismissals from sceptical investors who associate Johnson & Johnson (NYSE: JNJ) with baby powder and tear-free shampoo rather than cutting-edge medicines, there's a solid chance that its COVID-19 vaccine candidate will make billions. Don't let the delay in getting J&J's results fool you: Its coronavirus vaccine will have several advantages over others, if successful. Its vaccine will be stable for three months at refrigerator temperature, and it will require only one dose to do the job. The cost per dose will be around $10, which is quite cheaper than both Pfizer's $19.50 and Moderna's $32. AstraZeneca does plan to price its candidate $3 per dose but its trial is surrounded with confusion and recent controversy due to its partner in China. But the bottom line is that Johnson & Johnson doesn't even need its coronavirus vaccine to remain a profitable company that is in shareholder's good graces.

Even without vaccine, healthcare is essential

Everybody needs healthcare at some point in life. And when there's something that everyone needs, there's always a huge opportunity for investors. But as the pandemic has put the things we matter most to a halt such as hanging out with friends and hugging loved ones, this is literally big pharma's time to shine as the vaccine is what will allow us to return to normal and everything we hold dear.

This article is not a press release and is contributed by  IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure. IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: Contributors – IAM Newswire accepts pitches. If you're interested in becoming an IAM journalist contact:

The post 3 COVID Stocks Not to Neglect appeared first on IAM Newswire.


Related Articles (JNJ + MRNA)

View Comments and Join the Discussion!

Posted-In: IAM NewswireBiotech Markets General